Top

BMC Cancer

Published in:

Open Access 01-12-2024 | Botulinum Toxin | Research

Pulsatilla saponin D regulates ras-related C3 botulinum toxin substrate 3 (RAC3) to overcome resistance to paclitaxel in lung adenocarcinoma cells

Authors: Yanyan Lu, Wubin He, Xiaoxu Huang, Xuyang Xiao

Published in: BMC Cancer | Issue 1/2024

Abstract

Background

Paclitaxel, a tubulin-binding agent, is a Food and Drug Administration-approved first-line drug for the treatment of non-small cell lung cancer (NSCLC), for both squamous and non-squamous cell lung carcinoma, with paclitaxel/carboplatin + bevacizumab a common chemotherapy regimen for stage IV non-squamous NSCLC; however, primary or acquired resistance to paclitaxel is gradually increasing, leading to treatment failure.

Methods

Our results show that Ras-related C3 botulinum toxin substrate 3 (RAC3) is overexpressed in cultured paclitaxel-resistant cells and that RAC3 expression levels are negatively correlated with sensitivity of lung adenocarcinoma cells to paclitaxel. Pulsatilla saponin D could inhibit RAC3 expression, and we hypothesize that it may block paclitaxel resistance. Further, we found that treatment with paclitaxel combined with Pulsatilla saponin D, can overcome lung adenocarcinoma cell resistance to paclitaxel alone in cell culture and mouse xenograft models.

Behrend SJ, Giotopoulou GA, Spella M, Stathopoulos GT. A role for club cells in smoking-associated lung adenocarcinoma. Eur Resp Rev. 2021;30:210122. https://doi.org/10.1183/16000617.0122-2021.CrossRef

Yin H, Jing B, Xu D, Guo W, Sun B, Zhang J, Liao Y, Song H, Wang T, Liu S, et al. Identification of active bronchioalveolar stem cells as the cell-of-origin in lung adenocarcinoma. Cancer Res. 2022;82:1025–37. https://doi.org/10.1158/0008-5472.CAN-21-2445.CrossRefPubMed

Shi L, Tan X, Liu X, Yu J, Bota-Rabassedas N, Niu Y, Luo J, Xi Y, Zong C, Creighton C et al. (2021). Addiction to golgi-resident PI4P synthesis in chromosome 1q21.3-amplified lung adenocarcinoma cells. Proc Natl Acad Sci USA. 118:e2023537118. https://doi.org/10.1073/pnas.2023537118.

Wang X, Zhao X, Shi L, Wu Y, Zhang X, Fan Z, Shen B. IL6 pretreatment promotes chemosensitivity by eliminating quiescent cancer (stem) cells in lung adenocarcinoma. Clin Transl Med. 2020;10:e217. https://doi.org/10.1002/ctm2.217.CrossRefPubMedPubMedCentral

Kim JS, Kurie JM, Ahn Y-H. BMP4 depletion by miR-200 inhibits tumorigenesis and metastasis of lung adenocarcinoma cells. Mol Cancer. 2015;14:173. https://doi.org/10.1186/s12943-015-0441-y.CrossRefPubMedPubMedCentral

Pankova D, Jiang Y, Chatzifrangkeskou M, Vendrell I, Buzzelli J, Ryan A, Brown C, O’Neill E. RASSF1A controls tissue stiffness and cancer stem-like cells in lung adenocarcinoma. EMBO J. 2019;38:e100532. https://doi.org/10.15252/embj.2018100532.CrossRefPubMedPubMedCentral

Mao Y, Fan W, Hu H, Zhang L, Michel J, Wu Y, Wang J, Jia L, Tang X, Xu L, et al. MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells. J Hematol Oncol. 2019;12:106. https://doi.org/10.1186/s13045-019-0793-7.CrossRefPubMedPubMedCentral

Banerjee P, Xiao G-Y, Tan X, Zheng VJ, Shi L, Rabassedas MNB, Guo H, Liu X, Yu J, Diao L, et al. The EMT activator ZEB1 accelerates endosomal trafficking to establish a polarity axis in lung adenocarcinoma cells. Nat Comm. 2021;12:6354. https://doi.org/10.1038/s41467-021-26677-y.CrossRef

Zhou Y, Mu L, Liu X-L, Li Q, Ding L-X, Chen H-C, Hu Y, Li F-S, Sun W-J, He B-C, et al. Tetrandrine inhibits proliferation of colon cancer cells by BMP9/PTEN/PI3K/AKT signaling. Genes Dis. 2019;8:373–83. https://doi.org/10.1016/j.gendis.2019.10.017.CrossRefPubMedPubMedCentral

10.

Li H, Zhang Y, Lan X, Yu J, Yang C, Sun Z, Kang P, Han Y, Yu D. Halofuginone sensitizes lung cancer organoids to cisplatin via suppressing PI3K/AKT and MAPK signaling pathways. Front Cell Dev Biol. 2021;9:773048. https://doi.org/10.3389/fcell.2021.773048.CrossRefPubMedPubMedCentral

11.

Liang J, Li H, Han J, Jiang J, Wang J, Li Y, Feng Z, Zhao R, Sun Z, Lv B, et al. Mex3a interacts with LAMA2 to promote lung adenocarcinoma metastasis via PI3K/AKT pathway. Cell Death Dis. 2020;11:614. https://doi.org/10.1038/s41419-020-02858-3.CrossRefPubMedPubMedCentral

12.

Chen Z, Zhao T, Zhou L, Kang J, Guan Y, Yang M, Yang S, Liu H. Drug release in vivo and efficacy evaluation of a new colon targeted powder of total saponins of Pulsatilla. Biomed Pharmacother. 2020;129:110376. https://doi.org/10.1016/j.biopha.2020.110376.CrossRefPubMed

13.

Wang K, Tu Y, Wan J-B, Chen M, He C. Synergistic anti-breast cancer effect of Pulsatilla saponin D and camptothecin through interrupting autophagic-lysosomal function and promoting p62-mediated ubiquitinated protein aggregation. Carcinogenesis. 2020;41:804–16. https://doi.org/10.1093/carcin/bgz140.CrossRefPubMed

14.

Son MK, Jung KH, Hong S-W, Lee H-S, Zheng H-M, Choi MJ, Seo JH, Suh J-K, Hong S-S. SB365, Pulsatilla saponin D suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the AKT/mTOR signalling pathway. Food Chem. 2013;136:26–33. https://doi.org/10.1016/j.foodchem.2012.07.096.CrossRefPubMed

15.

Guan Z, Chen L, Zhou Y, Luo Y, Cui Y, Liu R, Shou B. The synergistic antitumour effect of multi-components from Pulsatilla chinensis saponins in NCI-H460 lung cancer cell line through induction of apoptosis. Pharmaceut Biol. 2020;58:427–37. https://doi.org/10.1080/13880209.2020.1761404.CrossRef

16.

Haataja L, Groffen J, Heisterkamp N. Identification of a novel Rac3-interacting protein C1D. Int J Mol Med. 1998;1:665–70. https://doi.org/10.3892/ijmm.1.4.665.CrossRefPubMed

17.

Costain G, Callewaert B, Gabriel H, Tan TY, Walker S, Christodoulou J, Lazar T, Menten B, Orkin J, Sadedin S, et al. De novo missense variants in Rac3 cause a novel neurodevelopmental syndrome. Genet Med. 2019;21:1021–6. https://doi.org/10.1038/s41436-018-0323-y.CrossRefPubMed

18.

He D, Xu L, Wu Y, Yuan Y, Wang Y, Liu Z, Zhang C, Xie W, Zhang L, Geng Z, et al. Rac3, but not Rac1, promotes ox-LDL induced endothelial dysfunction by downregulating autophagy. J Cell Physiol. 2020;235:1531–42. https://doi.org/10.1002/jcp.29072.CrossRefPubMed

19.

de Curtis I. The Rac3 GTPase in neuronal development, neurodevelopmental disorders, and cancer. Cells. 2019;8:1063. https://doi.org/10.3390/cells8091063.CrossRefPubMedPubMedCentral

20.

Donnelly SK, Cabrera R, Mao SPH, Christin JR, Wu B, Guo W, Bravo-Cordero JJ, Condeelis JS, Segall JE, Hodgson L, et al. Rac3 regulates breast cancer invasion and metastasis by controlling adhesion and matrix degradation. J Cell Biol. 2017;216:4331–49. https://doi.org/10.1083/jcb.201704048.CrossRefPubMedPubMedCentral

21.

Cheng C, Song D, Wu Y, Liu B. Rac3 promotes proliferation, migration and invasion via PYCR1/JAK/STAT signaling in bladder cancer. Front Mol Biosci. 2020;7:218. https://doi.org/10.3389/fmolb.2020.00218.CrossRefPubMedPubMedCentral

22.

Mira JP, Benard V, Groffen J, Sanders LC, Knaus UG. Endogenous, hyperactive Rac3 controls proliferation of breast cancer cells by a p21-activated kinase-dependent pathway. Proc Natl Acad Sci U S A. 2000;97:185–9. https://doi.org/10.1073/pnas.97.1.185.CrossRefPubMedPubMedCentral

23.

Mazieres J, Kowalski D, Luft A, Vicente D, Tafreshi A, Gümüş M, Laktionov K, Hermes B, Cicin I, Rodríguez-Cid J, et al. Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non-small-cell lung cancer. J Clin Oncol. 2020;38:271–80. https://doi.org/10.1200/JCO.19.01348.CrossRefPubMed

24.

Shi M, Gu A, Tu H, Huang C, Wang H, Yu Z, Wang X, Cao L, Shu Y, Wang H, et al. Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial. Ann Oncol. 2021;32:85–96. https://doi.org/10.1016/j.annonc.2020.10.479.CrossRefPubMed

25.

Jin Y, Chen Y, Tang H, Hu X, Hubert SM, Li Q, Su D, Xu H, Fan Y, Yu X, et al. Activation of PI3K/AKT pathway is a potential mechanism of treatment resistance in small cell lung cancer. Clin Cancer Res. 2022;28:526–39. https://doi.org/10.1158/1078-0432.CCR-21-1943.CrossRefPubMed

26.

Fang Y, Hu D, Li H, Hu J, Liu Y, Li Z, Xu G, Chen L, Jin Y, Yang S, et al. Synthesis, biological evaluation, and mode of action of Pulsatilla saponin D derivatives as promising anticancer agents. Front Pharmacol. 2019;10:1208. https://doi.org/10.3389/fphar.2019.01208.CrossRefPubMedPubMedCentral

27.

Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Brit J Cancer. 2001;85:1928–36. https://doi.org/10.1054/bjoc.2001.2179.CrossRefPubMedPubMedCentral

28.

Rubio MF, Lira MC, Rosa FD, Sambresqui AD, Güemes MCS, Costas MA. Rac3 influences the chemoresistance of colon cancer cells through autophagy and apoptosis inhibition. Cancer Cell Int. 2017;17:111. https://doi.org/10.1186/s12935-017-0483-x.CrossRefPubMedPubMedCentral

29.

Colo GP, Rosato RR, Grant S, Costas MA. Rac3 down-regulation sensitizes human chronic myeloid leukemia cells to TRAIL-induced apoptosis. FEBS Lett. 2007;581:5075–81. https://doi.org/10.1016/j.febslet.2007.09.052.CrossRefPubMed

30.

Hong SW, Jung KH, Lee H-S, Choi M-J, Son MK, Zheng H-M, Hong SS. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway. Cancer Sci. 2012;103(11):1929–37. https://doi.org/10.1111/j.1349-7006.2012.02409.CrossRefPubMedPubMedCentral

31.

Son MK, Jung KH, Lee HS, Lee H, Kim SJ, Yan HH, Ryu Y-L, Hong S-S. SB365, Pulsatilla saponin D suppresses proliferation and induces apoptosis of pancreatic cancer cells. Oncol Rep. 2013b;30:801–8. https://doi.org/10.3892/or.2013.2517.CrossRefPubMed

Title: Pulsatilla saponin D regulates ras-related C3 botulinum toxin substrate 3 (RAC3) to overcome resistance to paclitaxel in lung adenocarcinoma cells
Authors: Yanyan Lu
Wubin He
Xiaoxu Huang
Xuyang Xiao
Publication date: 01-12-2024
Publisher: BioMed Central
Keyword: Botulinum Toxin
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-11841-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Please log in to get access to this content

Other articles of this Issue 1/2024

Partial recovery of peripheral blood monocyte subsets in head and neck squamous cell carcinoma patients upon radio(chemo)therapy is associated with decreased plasma CXCL11

Exploration of lymph node recurrence patterns and delineation guidelines of radiation field in middle thoracic oesophageal carcinomas after radical surgery: a real-world study

Optimization of a mouse model of pancreatic cancer to simulate the human phenotypes of metastasis and cachexia

Expression of STAT3 and hypoxia markers in long-term surviving malignant glioma patients

Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review

Experiences and perceptions of men following breast cancer diagnosis: a mixed method systematic review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer